WANY
TCRT icon

Wealthspire Advisors (New York)’s Alaunos Therapeutics TCRT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$3 – 2693
2025
Q3 		$3 Buy
+1
New +$3 ﹤0.01% 3055

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Wealthspire Advisors (New York)'s TCRT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Alaunos Therapeutics (TCRT) in Q4 2025, closing a stake of 1 share — an estimated $3 sold.

Wealthspire Advisors (New York) first reported a position in TCRT in Q3 2025 and held it in 1 quarter. The position peaked at $3 in Q3 2025. 27 funds tracked by Wall St. Rank hold TCRT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Alaunos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1 Alaunos Therapeutics share in Q4 2025, an estimated $3.
  • Wealthspire Advisors (New York) first reported a position in Alaunos Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Alaunos Therapeutics position peaked at $3 in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.